Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States. Jara M, Aquilina T, Aupperle P, Rabinowicz AL Drug Healthc Patient Saf. 2015; 7:169-74. Epub 2015 Dec 15. PMID: 26719727. Abstract CommentRecommendBookmarkWatch